Vigil neuroscience. The average target predicts an increase of 1,003.
Vigil neuroscience William Blair : Buy. Their stock opened with $14. William Blair analyst S. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the About Vigil Neuroscience. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience Analyst Ratings. 64 million. All Analysts Top Analysts Total Analysts . is a clinical-stage biotechnology company. is the largest shareholder with 15% of shares Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain About Vigil Neuroscience Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain Vigil Neuroscience, Inc. Read why VIGL is a Hold. William Blair. 06, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. The last reported earnings were for reported on November 7, 2024 for Q3. Shares of NASDAQ:VIGL opened at $1. Previous; The Investor Relations website contains information about Vigil Neuroscience, Inc's business for stockholders, potential investors, and financial analysts. (VIGL) stock. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Filter results. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic - Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and Vigil Neuroscience, Inc. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Read Our Latest Research Report on VIGL. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Ivana is an accomplished pharmaceutical and biotechnology executive focused on corporate excellence and execution. Vigil Neuroscience, Inc. The low is $4 issued by Morgan Stanley on Vigil Neuroscience, Inc. currently has an average brokerage recommendation (ABR) of 1. Harnessing the power of microglia to transform treatments for neurodegenerative diseases | Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. That is a compound annual growth rate of -42. About Vigil Neuroscience Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. 04 to a high Vigil Neuroscience Inc. Don't Miss our Black Friday Offers: A high-level overview of Vigil Neuroscience, Inc. 01%. Jennifer Orthmann-Murphy of Penn Medicine and patient advocacy organizations; Sisters’ Hope Foundation, United Leukodystrophy Foundation, ALEX The Leukodystrophy Charity and Hunter’s Vigil Neuroscience, Inc. 49 and a fifty-two week high of $6. 22 based on the ratings of 10 analysts. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering Vigil Neuroscience Stock Performance. The high is $24 issued by Wedbush on November 8, 2024. (NASDAQ:VIGL) released interim data on Wednesday from its ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers. 06 earnings per share over the last four quarters. Vigil Neuroscience Incorporated is a microglia-focused company that develops disease-modifying therapeutics for rare and common neurodegenerative diseases. – Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 Management — Vigil Neuro About Us Vigil Neuroscience Inc. Shares of VIGL opened at $1. com. Upside +979. , where he led the development of its first therapeutic research programs as Chief Scientific Officer. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake Simply Wall St. Key developments include completing enrollment of 20 patients for the IGNITE Phase 2 trial of iluzanebart and surpassing 50 William Blair initiated coverage of Vigil Neuroscience (VIGL) with an Outperform rating and $18. 400 Technology Square, 10th Floor, Cambridge, MA, 02139, United States. Get the latest Vigil Neuroscience, Inc VIGL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 19/share. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience is registered under the ticker NASDAQ:VIGL . Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the About Vigil Neuroscience Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience, Inc. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the About Vigil Neuroscience. Vigil Vigil Neuroscience continues to focus on developing microglia-targeted therapies for neurodegenerative diseases, with a strategy to expand its pipeline through internal development and strategic Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain Vigil Neuroscience to Present at Upcoming September Investor Conferences WATERTOWN, Mass. 70M to $75. 23%. , March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. Info@vigilneuro. Its lead product candidate is VGL101 is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral William Blair analyst Sarah Schram initiated coverage of Vigil Neuroscience (VIGL) with an Outperform rating. Site by Show + Tell. 13M, a decrease of -81. William Blair started coverage on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report released on Wednesday, Marketbeat reports. Sanofi and Logos Capital are the most recent investors. Vigil Neuroscience is not owned by hedge funds. - Sanofi to invest $40 million at an as-converted price of $7. - Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. com Vigil Neuroscience outlines 2025 milestones for VG-3927 and iluzanebart trials in Alzheimer's and ALSP. The stock was purchased at an average price of $1. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. , Jan. What is Vigil Neuroscience's EPS forecast for next year? Vigil Neuroscience, Inc. 11, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. Nachrichten zur Aktie Vigil Neuroscience Inc Registered Shs | A3DCFS | VIGL | US92673K1088 Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. 67 fair value estimate. About Vigil Neuroscience. Schram forecasts that the company will post Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The brokerage issued an outperform rating on the · Experience: Vigil Neuroscience · Education: Columbia University in the City of New York · Location: Bethesda · 500+ connections on LinkedIn. Vigil Neuroscience is developing novel drugs to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the brain’s sentinel immune cells. (NASDAQ:VIGL - Free Report) - Research analysts at William Blair issued their Q4 2024 earnings estimates for Vigil Neuroscience in a research report issued on Wednesday, January 8th. The interim data was only from 6 patients, but the drug was shown to be safe and tolerable, along with the fact that there Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the VIGIL NEUROSCIENCE AKTIE und aktueller Aktienkurs. – On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience, Inc. The company reported significant progress in its two TREM2 agonist programs and secured a $40 million strategic investment from Sanofi. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management Vigil Neuroscience is the world’s first microglia-focused therapeutics company. 75. VIGL has generated -$2. As of December 3, 2024, the average one-year price target for Vigil Neuroscience is $16. ) Industry: PHARMACEUTICAL PREPARATIONS: Employees: 34: Founded: Vigil Neuroscience, a company dedicated to improving the lives of people living with neurodegenerative diseases, is developing a new potential therapy for ALSP called iluzanebart (VGL101). Wed 8am - 5pm . Prior to joining Vigil, Jennifer was Chief Financial Officer of Solid Biosciences, where she played a key role in transforming Solid from a private, preclinical company to a publicly-held, clinical-stage biotech company. At Vigil Neuroscience, we celebrate inclusion and the unique and diverse contributions of each person regardless of our ethnicity, race, sex, gender identity and expression, national origin, age, languages spoken, veteran’s status, color, religion, disability, sexual orientation or any other protected category or belief system. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering Vigil Neuroscience, Inc. 96% Upside. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our Vigil Neuroscience has made great progress in advancing its pipeline. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vigil Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy. 12, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. The forecasts range from a low of $4. Vigil Neuroscience Price Performance. View Petra Kaufmann, MD’s profile on LinkedIn Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. 35% from the current stock price of 1. is a clinical-stage biotechnology company dedicated to developing treatments for neurodegenerative diseases by targeting microglial cells in the brain, with a focus on Headquarters 100 Forge Road Suite 700 Watertown, MA 02472 +1 857 254 4445 info@vigilneuro. If you're interested in participating in either study or would like more information, we'd love to hear from you. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience 6 Vigil Neuroscience is a clinical-stage microglia-focused therapeutics company Founded ~3 years ago in July 2020 Our purpose: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the brain’s sentinel immune cells Precision-based strategy for developing microglia therapeutics VGL101 –Antibody Agonist of TREM2 with a Compelling Profile 6 Human mAb: high TREM2 selectivity; sub-nanomolar potency Induces genes specific for microglia identity & function in CNS Brain penetration Experienced biologist with greater than 10 years of drug discovery expertise in · Experience: Vigil Neuroscience · Education: Princeton University · Location: Greater Boston · 500 JMP Securities reaffirmed their market outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a research note released on Tuesday morning,Benzinga reports. The 4 analysts with 12-month price forecasts for Vigil Neuroscience stock have an average target of 19. 06. 71 per share, with a total value of $20,520. com CAMBRIDGE, Mass. Share your ideas and get valuable insights from the community of like minded traders and investors Vigil Neuroscience (NASDAQ:VIGL) has a recorded net income of -$82. Mon 8am - 5pm . has a fifty-two week low of $1. 49 and a 1 year high of $6. At the heart of its . 00 in its Jan 7, 2022 IPO. Quiver AI Summary. - Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience (NASDAQ: VIGL) highlighted its 2024 achievements and 2025 milestones. , July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. CAMBRIDGE, Mass. Analyst Firm Rating Rating Action Price Target Upside Date; Sarah Schram. They About Vigil Neuroscience Vigil Neuroscience is a clinical-stage, microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. , a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. VIGL released interim data on Wednesday from its ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers. 47%. 79 on Monday. The Investor Relations website contains information about Vigil Neuroscience, Inc's business for stockholders, potential investors, and financial analysts. Columns. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Gray joins Vigil from Inscopix, Inc. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases NasdaqGS:VIGL Earnings and Revenue Growth November 7th 2024. The Vigil Neuroscience, Inc. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases Vigil Neuroscience, Inc. has announced its plans to report data from its Get the latest Vigil Neuroscience Inc (VIGL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver Since the IPO on January 7, 2022, Vigil Neuroscience's market cap has decreased from $395. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its Vigil Neuroscience, Inc. WATERTOWN, Mass. Vigil is developing a unique TREM2-targeting therapeutics pipeline to treat Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the About Vigil Neuroscience. We are utilizing the tools of modern neuroscience drug development across multiple Find out the direct holders, institutional holders and mutual fund holders for Vigil Neuroscience, Inc. (Note: Vigil Neuroscience, Inc. P. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The average target predicts an increase of 1,003. 47), a clinical-stage biopharma focused on developing microglial-targeting therapeutics by leveraging genetic insights into degenerative disorders of the central nervous system (CNS). 00. Hours. 6, 2022, at $14 – $1 below the bottom of its $15-to-$17 price range – on 7 million shares, the same number of shares in the prospectus, to raise $98 million. Our data shows that Atlas Venture L. Who are Vigil Neuroscience 's competitors? Alternatives and possible competitors Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience, Inc. Track Vigil Neuroscience Inc (VIGL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Analyst Performance. VG-3927 is a novel small molecule TREM2 agonist William Blair initiated research coverage of Vigil Neuroscience, Inc. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. - On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 The Investor Relations website contains information about Vigil Neuroscience, Inc's business for stockholders, potential investors, and financial analysts. (VIGL). The company was founded on June 22, 2020 and is CAMBRIDGE, Mass. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. All Analysts Top Analysts Stock Price Forecast. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its About Vigil Neuroscience. , a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the The Investor Relations website contains information about Vigil Neuroscience, Inc's business for stockholders, potential investors, and financial analysts. Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus; Vigil Neuroscience, Inc. Price Target . – Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – Vigil Neuroscience, Inc. Common Stock (VIGL) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its Discover real-time Vigil Neuroscience, Inc. Ratings History. Strong Buy. Contact; Privacy Policy Analyst Price Forecast Suggests 594. , Oct. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the In this article, we are going to take a look at where Vigil Neuroscience, Inc. She has over 20 years of senior management experience in financing, strategic partnerships, M&A, clinical When was the last funding round for Vigil Neuroscience? Vigil Neuroscience closed its last funding round on Jun 27, 2024 from a Post-IPO Equity round. Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience, Inc. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases View Vigil Neuroscience, Inc VIGL investment & stock information. 5. • 24 days ago Vigil Neuroscience to Present at Guggenheim Vigil Neuroscience (VIGL) is scheduled to report earnings on March 25, 2025. Following the completion of the acquisition, the director now owns Vigil Neuroscience | 9,022 followers on LinkedIn. Tue 8am - 5pm . com Vigil Neuroscience, Inc. The firm has a 50 day Headquarters 100 Forge Road Suite 700 Watertown, MA 02472 +1 857 254 4445 info@vigilneuro. Vigil Neuroscience is a microglia-focused therapeutics company with a mission to treat rare and common neurodegenerative disease such as Alzheimer’s by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Vigil Neuroscience is a clinical-stage, microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. (VIGL $2. – On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of Headquarters 100 Forge Road Suite 700 Watertown, MA 02472 +1 857 254 4445 info@vigilneuro. (NASDAQ:VIGL - Get Free Report) Director Haeberlein Samantha L. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Vigil Neuroscience has a 1 year low of $1. Budd acquired 12,000 shares of the firm's stock in a transaction that occurred on Thursday, December 19th. Vigil Neuroscience is funded by 15 investors. VG-3927 is a novel small molecule TREM2 agonist to treat Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience, Inc. The company's approach pivots on rejuvenating the microglia's alertness—the brain's protective immune cells. See information about Amgen’s Forward-Looking Statements here. , a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment About Vigil Neuroscience. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience Inc. 79 on Friday. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the According to a recent announcement, the FDA has removed a partial clinical hold on Vigil Neuroscience’s ongoing phase 1 trial (NCT06343636) assessing its investigational therapy VG-3927 to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on patients with Alzheimer disease (AD), based on a complete About Vigil Neuroscience. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its © 2025 ATLAS VENTURE, All Rights Reserved. Vigil Neuroscience Inc has a consensus price target of $17. , Aug. Biotech Stocks in 2024: Growth Prospects, Key Players WATERTOWN, Mass. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the So Vigil Neuroscience, Inc. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our Vigil Neuroscience, Inc. Consensus Rating . 44 per share of common stock-- Sanofi to receive an exclusive right of first negotiation for license of Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. 30 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold Vigil Neuroscience, Inc. VG-3927 is a novel small molecule TREM2 agonist About Vigil Neuroscience. , priced its IPO on Jan. 79. technincal analysis shows the sell today, and its 1 week rating is sell. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of About Vigil Neuroscience. - Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts Vigil Neuroscience, Inc. About Vigil Neuroscience Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Stay ahead with Nasdaq. . Investor Relations — Vigil Neuroscience, Inc Phase 1, First-in-Human, Single- and Multiple-Ascending Dose Study of a Novel Orally Administered TREM2 Agonist (VG-3927) in Healthy Volunteers: Interim Results This is a recording from our January 2023 Community Webinar providing an update for the ALSP community including Vigil Neuroscience leadership as well as Dr. About Vigil Neuroscience Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the Vigil Neuroscience Stock Forecast. (NASDAQ:VIGL) stands against the other biotech penny stocks. , an organization dedicated to biotechnological advancements, is proactively channeling its efforts towards generating therapies for both rare and prevalent neurodegenerative ailments. Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the Vigil Neuroscience, Inc. $19. 75, with a low estimate of 16 and a high estimate of 24. jonx lxerq sergaw onmk fbx ekzi aeyt aikcq fpzo hcwmxy